Insider Selling: Becton, Dickinson and Company (NYSE:BDX) CEO Sells 4,152 Shares

Becton, Dickinson and Company (NYSE:BDX) CEO Thomas Polen, Jr. sold 4,152 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX traded up $1.20 during trading on Friday, reaching $183.16. 1,008,994 shares of the company traded hands, compared to its average volume of 2,680,036. The stock has a market cap of $50.47 billion, a P/E ratio of 55.17, a PEG ratio of 12.94 and a beta of 0.19. The firm’s fifty day simple moving average is $157.20 and its 200 day simple moving average is $161.55. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The firm had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.84% and a net margin of 4.52%.The company’s revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be given a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 126.51%.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several institutional investors and hedge funds have recently added to or reduced their stakes in BDX. Larson Financial Group LLC raised its position in Becton, Dickinson and Company by 1.7% during the fourth quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock worth $627,000 after acquiring an additional 53 shares during the period. Camelot Portfolios LLC increased its stake in shares of Becton, Dickinson and Company by 1.5% during the fourth quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier’s stock worth $688,000 after purchasing an additional 54 shares in the last quarter. Atlantic Union Bankshares Corp raised its position in shares of Becton, Dickinson and Company by 0.9% during the 4th quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock worth $1,185,000 after purchasing an additional 57 shares during the last quarter. PDS Planning Inc raised its position in shares of Becton, Dickinson and Company by 3.6% during the 4th quarter. PDS Planning Inc now owns 1,678 shares of the medical instruments supplier’s stock worth $326,000 after purchasing an additional 58 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC lifted its stake in Becton, Dickinson and Company by 3.7% in the 2nd quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock valued at $256,000 after buying an additional 60 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. TD Cowen boosted their target price on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Wells Fargo & Company raised their price target on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Royal Bank Of Canada lifted their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a report on Thursday. Citigroup reissued a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $185.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.